These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25366565)

  • 1. Notch signaling in serous ovarian cancer.
    Groeneweg JW; Foster R; Growdon WB; Verheijen RH; Rueda BR
    J Ovarian Res; 2014 Nov; 7():95. PubMed ID: 25366565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Notch signalling in ovarian angiogenesis.
    Xie Q; Cheng Z; Chen X; Lobe CG; Liu J
    J Ovarian Res; 2017 Mar; 10(1):13. PubMed ID: 28284219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
    Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
    Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting notch signaling pathway in cancer: clinical development advances and challenges.
    Takebe N; Nguyen D; Yang SX
    Pharmacol Ther; 2014 Feb; 141(2):140-9. PubMed ID: 24076266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
    Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
    Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch3 pathway alterations in ovarian cancer.
    Hu W; Liu T; Ivan C; Sun Y; Huang J; Mangala LS; Miyake T; Dalton HJ; Pradeep S; Rupaimoole R; Previs RA; Han HD; Bottsford-Miller J; Zand B; Kang Y; Pecot CV; Nick AM; Wu SY; Lee JS; Sehgal V; Ram P; Liu J; Tucker SL; Lopez-Berestein G; Baggerly KA; Coleman RL; Sood AK
    Cancer Res; 2014 Jun; 74(12):3282-93. PubMed ID: 24743243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.
    Allam H; Johnson BP; Zhang M; Lu Z; Cannon MJ; Abbott KL
    J Biol Chem; 2017 Sep; 292(39):16351-16359. PubMed ID: 28842505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch signaling: an emerging therapeutic target for cancer treatment.
    Yuan X; Wu H; Xu H; Xiong H; Chu Q; Yu S; Wu GS; Wu K
    Cancer Lett; 2015 Dec; 369(1):20-7. PubMed ID: 26341688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.
    Virant-Klun I; Kenda-Suster N; Smrkolj S
    J Ovarian Res; 2016 Mar; 9():12. PubMed ID: 26940129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.
    Delaney JR; Patel C; McCabe KE; Lu D; Davis MA; Tancioni I; von Schalscha T; Bartakova A; Haft C; Schlaepfer DD; Stupack DG
    Oncotarget; 2015 Oct; 6(31):31104-18. PubMed ID: 26418751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Notch signaling for cancer therapeutic intervention.
    Shao H; Huang Q; Liu ZJ
    Adv Pharmacol; 2012; 65():191-234. PubMed ID: 22959027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway.
    Liu Z; Zhu Y; Li F; Xie Y
    Protoplasma; 2020 May; 257(3):901-910. PubMed ID: 31897811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer.
    Akbarzadeh M; Akbarzadeh S; Majidinia M
    Pathol Res Pract; 2020 Nov; 216(11):153158. PubMed ID: 32829107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch signaling pathway in ovarian cancer.
    Rose SL
    Int J Gynecol Cancer; 2009 May; 19(4):564-6. PubMed ID: 19509550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
    Crane LM; Arts HJ; van Oosten M; Low PS; van der Zee AG; van Dam GM; Bart J
    Cell Oncol (Dordr); 2012 Feb; 35(1):9-18. PubMed ID: 21647742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.
    Pylväs-Eerola M; Liakka A; Puistola U; Koivunen J; Karihtala P
    Anticancer Res; 2016 Jul; 36(7):3425-31. PubMed ID: 27354603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.